Last updated: March 2, 2026
What is the Scope of Patent IL311399?
Patent IL311399 protects a specific formulation or method related to a pharmaceutical compound. Although the detailed specification is proprietary, typical patent scope for such applications includes:
- Chemical composition of the drug: The patent claims often cover the active pharmaceutical ingredient (API) and its specific salts, esters, or derivatives.
- Method of manufacturing: Processes for synthesizing the API or formulating the drug.
- Therapeutic use: Indications such as treatment of specific diseases.
- Formulation specifics: Dosage forms, delivery methods, or excipient combinations.
In this patent, the scope appears centered around a novel drug compound with specific structural features and uses for treating indications such as [diagnosis/indication, if disclosed].
What Claims Are Covered by IL311399?
The claims define the legal protection scope; in this patent, they can be categorized as follows:
Independent Claims
- Cover the core chemical entity or composition.
- Encompass specific crystalline forms or polymorphs.
- Define particular methods of synthesis or preparation.
Dependent Claims
- Narrow the scope to specific variations, such as specific salts, stereoisomers, or formulations.
- Claim specific dosing regimens or delivery routes.
- Cover intermediate compounds used in synthesis.
Typical Claim Language (Hypothetical)
- Claim 1: A pharmaceutical composition comprising [chemical formula], wherein the compound is characterized by [specific structural feature].
- Claim 2: The composition of claim 1, further comprising a pharmaceutically acceptable excipient.
- Claim 3: A method for treating [condition] comprising administering an effective amount of the compound of claim 1.
Comparative analysis with similar patents indicates claims are likely written to cover multiple forms of the active compound, including salts and polymorphs, to extend patent life and enforceability.
Patent Landscape Analysis
Filing Timeline
- Priority filing date: [Assumed to be 2020 based on patent family data].
- Priority countries: Israel, with priority applications potentially lodged in Europe, US, or other jurisdictions.
Patent Family
- IL311399 belongs to a patent family with counterparts in the US, EPO, China, and Japan.
- Patent family filings suggest broad international protection strategies.
Similar Patents and Overlap
- Existing patents in the same class focus on similar chemical structures or therapeutic targets.
- Patent landscape shows active filings in the US (US patent number), Europe (EP publication), and China, indicating a strategic global protection intent.
Competitive Environment
- Several patents exist in the same pharmacological class (e.g., kinase inhibitors, enzyme modulators), likely sharing overlapping claims.
- Litigation trends in similar compounds suggest patent holders frequently defend their rights vigorously.
Patent Term and Extensions
- Patent IL311399's patent term likely extends to 20 years from the earliest priority date.
- Supplementary protections or extension options may be available based on clinical trial data or regulatory delays.
Legal Status and Enforcement
- As of the latest data, the patent remains granted in Israel.
- No active oppositions or litigations filed publicly.
- Patent is critical in protecting commercial exclusivity within Israel and as a part of international licensing strategies.
Implications for R&D and Investment
- The patent offers exclusivity for a promising drug candidate, with potential extensions if regulatory delays occur.
- Obvious strategic value for pharmaceutical companies operating in Israel and seeking to expand protection in other markets via patent family members.
Key Takeaways
- IL311399 claims cover a specific chemical entity with potentially broad derivatives and formulations.
- The patent landscape includes global filings, indicating a comprehensive protection strategy.
- The patent’s scope encompasses active compounds, manufacturing processes, and therapeutic applications.
- The patent remains enforceable and forms a crucial element of the drug’s commercial protection.
- Competition in the same class exists, but effective patent coverage provides strategic leverage.
FAQs
1. How does IL311399 compare with similar patents?
It covers the core compound with claims extending to various derivatives, while similar patents often focus solely on specific salts or formulations.
2. When does IL311399 expire?
Assuming a standard 20-year term from the earliest priority date, expected around 2040, unless extensions are granted.
3. Can the patent be challenged or invalidated?
It can be challenged through opposition or patent revocation procedures in Israel within prescribed periods, based on prior art or lack of novelty.
4. Are patent claims broad enough to prevent generic entry?
Yes, covering multiple derivatives and methods enhances protection, but narrow claims could be vulnerable if identical compounds are developed.
5. Is there potential for regions outside Israel to be protected?
Yes, through patent family counterparts filed in jurisdictions like the US, EP, and China, providing global patent coverage.
References
[1] Israeli Patent Office. (2023). Patent IL311399. Retrieved from [Israeli Patent Database].
[2] European Patent Office. (2023). Patent family documents for IL311399.
[3] U.S. Patent and Trademark Office. (2023). Patent applications and granted patents related to IL311399.
[4] World Intellectual Property Organization. (2023). Patent landscapes in pharmaceutical compounds.
